These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 503884)

  • 41. [Antithrombogenic activity of the vascular wall, hemostasis, and rheological characteristics of blood in patients with unstable angina pectoris and various types of hyperlipoproteinemia].
    Kirichuk VF; Voskoboĭ IV
    Ter Arkh; 2000; 72(12):47-50. PubMed ID: 11201832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical features of lipoprotein disorders.
    Lloyd JK
    Ric Clin Lab; 1982; 12(1):97-100. PubMed ID: 7089428
    [No Abstract]   [Full Text] [Related]  

  • 44. Genetic hyperlipidemia and atherosclerosis.
    Stone NJ
    Artery; 1979 May; 5(5):377-97. PubMed ID: 262162
    [No Abstract]   [Full Text] [Related]  

  • 45. [Familial disorders of lipid metabolism in childhood].
    Herrmann W; Biermann J
    Z Arztl Fortbild (Jena); 1986; 80(17):725-8. PubMed ID: 3811401
    [No Abstract]   [Full Text] [Related]  

  • 46. Very low density lipoprotein (VLDL) pattern in primary hyperlipoproteinaemia type IIb and type IV.
    Kłosiewicz-Latoszek L; Naruszewicz M; Cybulska B; Szostak WB; Chotkowska E
    Mater Med Pol; 1979; 11(3):230-4. PubMed ID: 232894
    [No Abstract]   [Full Text] [Related]  

  • 47. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [From clinical tests to etiology: analysis of clinical features. Deficiency of apolipoproteins].
    Yamamura T; Yamamoto A
    Rinsho Byori; 1987 Dec; Spec No 75():93-108. PubMed ID: 3448286
    [No Abstract]   [Full Text] [Related]  

  • 49. Behaviour of uricemia in hyperlipoproteinemic subjects.
    Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
    Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenesis and management of lipoprotein disorders.
    Schaefer EJ; Levy RI
    N Engl J Med; 1985 May; 312(20):1300-10. PubMed ID: 3887163
    [No Abstract]   [Full Text] [Related]  

  • 51. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 52. [The effect of genetic factors on blood lipoprotein levels].
    Raslová K; Oravec S; Kolesár P; Lukácová M
    Bratisl Lek Listy; 1985 May; 83(5):553-8. PubMed ID: 4027713
    [No Abstract]   [Full Text] [Related]  

  • 53. [Physiopathology of the process of cholesterol esterification].
    Opincaru A; Vlaicu R; Tapalagă D; Cucuianu M
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(3):193-200. PubMed ID: 41301
    [No Abstract]   [Full Text] [Related]  

  • 54. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
    Sale JK; Johnstone JH
    Ann Clin Biochem; 1981 Mar; 18 (Pt 2)():71-5. PubMed ID: 7259072
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP; Soltys G; Mangel R; Kwiterovitch P; Sniderman AD
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract]   [Full Text] [Related]  

  • 57. Fatty acid composition and action of serum lipoproteins on the PGI2-formation after various oil diets in hyperlipoproteinemia.
    Honigmann G; Schimke E; Schliack V; Beitz J; Förster W; Fischer S; Hora C; Hanefeld M
    Biomed Biochim Acta; 1984; 43(8-9):S443-6. PubMed ID: 6393974
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of type IIa and type V hyperlipoproteinemia and of a normal volunteer by continuous LDL-apheresis.
    Riesen WF; Sturzenegger E; Imhof C; Descoeudres C; Mordasini R; Oetliker OH
    Prog Clin Biol Res; 1988; 255():337-46. PubMed ID: 3422496
    [No Abstract]   [Full Text] [Related]  

  • 59. [Effect of vitamin E on the changes in plasma lipid peroxides and platelet aggregation in patients with hyperlipoproteinemia].
    Dworski R; Domagała B; Hartwich J; Radwan J; Grzywacz M; Szczeklik A
    Pol Arch Med Wewn; 1986 Jun; 75(6):393-401. PubMed ID: 3808976
    [No Abstract]   [Full Text] [Related]  

  • 60. [Musculoskeletal symptoms in patients with primary hyperlipoproteinemia. A prelimary study].
    Brekke SE; Kogstad OA
    Tidsskr Nor Laegeforen; 1979 Oct; 99(29):1444-6. PubMed ID: 516016
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.